ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Blistering Resignation Letters Declare CPRIT Outside Mainstream of Science

October 12, 2012

Early ADT Doesn’t Offer Survival Advantage—ASCO

April 27, 2007

Conversation with The Cancer Letter: Is Republican Control Better Than Two-Party Stalemate?

December 19, 2014

Want To Know What Cancer Research Projects Are Going On? CRESPAC Can Describe More Than 5,000

January 2, 1976

Waldmann, Columbia, Netherland, Receive Bristol-Myers Awards

April 17, 1992

Longer List of DCPC Spending Plans $40 Mll Increase

December 10, 1993